Search Results for "diagnosis"
Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.
More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.
For more information about our FDA-approved therapies, please see the Full Prescribing Information:
Vutrisiran Treatment in Patients with Transthyretin Amyloidosis with Cardiomyopathy
This asset represents the HELIOS-B primary results, published in the New England Journal of Medicine, in slide deck form.
This asset represents the HELIOS-B primary results, published in the New England Journal of Medicine, in slide deck form.
ATTR Management Guidelines
This deck highlights published guidelines on diagnosis, treatment and disease management of ATTR.
This deck highlights published guidelines on diagnosis, treatment and disease management of ATTR.
Diagnosing AHP Infographic
This infographic discusses the clinical and demographic presentation of an AHP patient and how to assess for AHP diagnosis.
This infographic discusses the clinical and demographic presentation of an AHP patient and how to assess for AHP diagnosis.
Identifying AHP module
This educational module will illustrate patients with AHP, describe common AHP symptoms and summarize how patients present to the various specialties involved in managing these patients
This educational module will illustrate patients with AHP, describe common AHP symptoms and summarize how patients present to the various specialties involved in managing these patients
Diagnosing PH1 Infographic
This infographic discusses the clinical and demographic presentation of a PH1 patient and how to assess for PH1 diagnosis
This infographic discusses the clinical and demographic presentation of a PH1 patient and how to assess for PH1 diagnosis
Potential Predictors of PH1 in Pediatric Patients
The handout details potential clinical characteristics that pediatric patients may present with which should warrant suspicion for PH1.
The handout details potential clinical characteristics that pediatric patients may present with which should warrant suspicion for PH1.
ATTR symptoms and manifestations early indicators
This deck highlights early indicators of ATTR and systemic manifestations.
This deck highlights early indicators of ATTR and systemic manifestations.
Musculoskeletal Manifestations Associated with ATTR Amyloidosis
This slide deck provides disease education on ATTR amyloidosis, focusing on the musculoskeletal manifestations associated with the disease and their importance for early diagnosis and patient care.
This slide deck provides disease education on ATTR amyloidosis, focusing on the musculoskeletal manifestations associated with the disease and their importance for early diagnosis and patient care.
Explore ATTR-CM
This slide deck presents of overview of ATTR amyloidosis, covering pathophysiology, disease manifestations and the clinical burden of ATTR-CM.
This slide deck presents of overview of ATTR amyloidosis, covering pathophysiology, disease manifestations and the clinical burden of ATTR-CM.
ATTR Screening and Carrier Management
This deck highlights tools for ATTR screening and recommendations for the management of hATTR carriers.
This deck highlights tools for ATTR screening and recommendations for the management of hATTR carriers.
Hereditary ATTR Amyloidosis: A Closer Look at the V1221 Variant
V122I is the most common variant of hATTR amyloidosis in the United States and is most prevalent in patients of African American descent. Compared to other variants, patients with the V122I variant experience significant disease burden and poorer outcomes.
V122I is the most common variant of hATTR amyloidosis in the United States and is most prevalent in patients of African American descent. Compared to other variants, patients with the V122I variant experience significant disease burden and poorer outcomes.
Diagnosing AHP
AHP Diagnosis
AHP Diagnosis
ASPIRE: Amyloidosis Industry Collaborative
ASPIRE: Amyloidosis Industry Collaborative convenes leading companies to address some of the most urgent issues faced by the amyloidosis community. Through partnership we are driven to shift the discourse and demonstrate what can be done when leaders work together on behalf of rare disease patients.
ASPIRE aims to accelerate progress in the areas of diagnosis, care, and addressing health disparities through collaborative project design and shared resources, arriving at solutions that address common challenges and unmet need.
ASPIRE: Amyloidosis Industry Collaborative convenes leading companies to address some of the most urgent issues faced by the amyloidosis community. Through partnership we are driven to shift the discourse and demonstrate what can be done when leaders work together on behalf of rare disease patients. ASPIRE aims to accelerate progress in the areas of diagnosis, care, and addressing health disparities through collaborative project design and shared resources, arriving at solutions that address common challenges and unmet need.
ATTR Disease Management
This deck highlights management and monitoring of patients with ATTR.
This deck highlights management and monitoring of patients with ATTR.
Understanding ATTR Amyloidosis
Understanding ATTR amlyloidosis: This slide deck highlights an overview of ATTR amyloidosis pathophysiology, symptom onset and prevalence
Understanding ATTR amlyloidosis: This slide deck highlights an overview of ATTR amyloidosis pathophysiology, symptom onset and prevalence
